Verastem (VSTM) EBT (2011 - 2026)
Verastem's quarterly EBT came in at -$44.0 million in Q1 2026, down 1.33% year-on-year from -$44.6 million in Q1 2025, and down 151.53% quarter-over-quarter from $85.4 million in Q4 2025.
Verastem has reported EBT for 16 years, with the latest figure at -$44.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 1.33% year-over-year to -$44.0 million; the trailing twelve-month figure through Mar 2026 stood at -$41.5 million (up 68.29% YoY), and the FY2025 full-year result was -$209.5 million, down 60.57% from the prior year.
- EBT for Q1 2026 stood at -$44.0 million, down from $85.4 million in the prior quarter.
- The five-year high for EBT was $85.4 million in Q4 2025, with the low at -$44.0 million in Q1 2026.
- Average EBT over 5 years is -$21.4 million, with a median of -$22.0 million recorded in 2022.
- Peak annual rise in EBT reached 368.68% in 2025, while the deepest fall reached 133.52% in 2025.
- Tracing VSTM's EBT over 5 years: stood at -$16.8 million in 2022, then slumped by 80.88% to -$30.4 million in 2023, then declined by 4.53% to -$31.8 million in 2024, then jumped by 368.68% to $85.4 million in 2025, then tumbled by 151.53% to -$44.0 million in 2026.
- The last three EBT figures came in at -$44.0 million (Q1 2026), $85.4 million (Q4 2025), and -$39.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | -43.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.98 Mn |
| Dec 31, 2025 | 85.35 Mn |
| Sep 30, 2025 | -39.85 Mn |
| Jun 30, 2025 | -43.04 Mn |
| Mar 31, 2025 | -43.41 Mn |
| Dec 31, 2024 | -31.77 Mn |
| Sep 30, 2024 | -37.35 Mn |
| Jun 30, 2024 | -18.43 Mn |
| Mar 31, 2024 | -27.82 Mn |
| Dec 31, 2023 | -30.39 Mn |
| Sep 30, 2023 | -20.19 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.14 Mn |
| Dec 31, 2022 | -16.80 Mn |
| Sep 30, 2022 | -18.11 Mn |
| Jun 30, 2022 | -21.96 Mn |
| Mar 31, 2022 | -16.99 Mn |
| Dec 31, 2021 | -16.48 Mn |
| Sep 30, 2021 | -22.79 Mn |
| Jun 30, 2021 | -16.90 Mn |
| Mar 31, 2021 | -15.03 Mn |
| Dec 31, 2020 | -19.67 Mn |
| Sep 30, 2020 | 13.14 Mn |
| Jun 30, 2020 | -23.01 Mn |
| Mar 31, 2020 | -37.99 Mn |
| Dec 31, 2019 | -38.13 Mn |
| Sep 30, 2019 | -30.14 Mn |
| Jun 30, 2019 | -42.19 Mn |
| Mar 31, 2019 | -38.10 Mn |
| Dec 31, 2018 | -36.91 Mn |
| Sep 30, 2018 | -21.67 Mn |
| Jun 30, 2018 | -18.37 Mn |
| Mar 31, 2018 | -21.05 Mn |
| Dec 31, 2017 | -18.24 Mn |
| Sep 30, 2017 | -23.13 Mn |
| Jun 30, 2017 | -13.44 Mn |
| Mar 31, 2017 | -13.01 Mn |
| Dec 31, 2016 | -11.66 Mn |
| Sep 30, 2016 | -7.92 Mn |
| Jun 30, 2016 | -8.57 Mn |
| Mar 31, 2016 | -8.29 Mn |
| Dec 31, 2015 | -11.86 Mn |
| Sep 30, 2015 | -15.45 Mn |
| Jun 30, 2015 | -15.38 Mn |
| Mar 31, 2015 | -15.18 Mn |
| Dec 31, 2014 | -13.95 Mn |
| Sep 30, 2014 | -13.33 Mn |
| Jun 30, 2014 | -13.02 Mn |
| Mar 31, 2014 | -13.06 Mn |
| Dec 31, 2013 | -11.32 Mn |
| Sep 30, 2013 | -10.59 Mn |
| Jun 30, 2013 | -10.25 Mn |
| Mar 31, 2013 | -9.04 Mn |
| Dec 31, 2012 | -7.92 Mn |
| Sep 30, 2012 | -10.37 Mn |
| Jun 30, 2012 | -6.83 Mn |
| Mar 31, 2012 | -6.87 Mn |
| Dec 31, 2011 | -6.02 Mn |
| Sep 30, 2011 | -4.05 Mn |
| Jun 30, 2011 | -2.49 Mn |
| Mar 31, 2011 | -1.15 Mn |